EUVIMEDEUVIMED entdecken
Crossref

Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity

José Luis Vique‐Sánchez, Paola Guadalupe López Lujano, Karla Alejandra Rodríguez Fonseca, Claudia Guadalupe Benítez‐Cardoza

ChemistrySelect · 25.04.2023 · 8 (16)

DOI: 10.1002/slct.202300196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 20.04.2023. Verfasst von José Luis Vique‐Sánchez und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholecystokinin (CCK) is a peptide family that functions pancreatic enzyme secretion, gallbladder contraction, intestinal motility, satiety, and stomach acid secretion. The CCK peptides are derived from pro‐CCK with a specific amino acid sequence (Asp, Tyr, Met, Gly, Trp, Met, Asp, and Phe) at their C‐terminus, where the Tyr residue is sulfated. The CCK peptides are ligands of the CCK receptors 1 (CCK1) and 2 (CCK2). In this study, we propose an approach for treating overweight and obese patients, preventing or reducing CCK1 activation using compounds that specifically interact with CCK peptides to regulate their interactions with CCK1. The compounds were selected by molecular docking using a chemical library with the selected residues (Asp, Tyr, Met, Gly, Trp, Met, Asp, and Phe) in CCK. Their effects were evaluated in a diet‐induced obese mice model. We show that compounds K2 and K5 decreased and maintained the body weight of the diet‐induced obese mice model, respectively, likely by preventing/hindering interactions between CCK peptides and CCK1, modifying its activity. This study demonstrates another approach to treating overweight and obesity by regulating CCK1 functions. The K2 and K5 compounds have properties supporting their continued development as new drugs against these risk factors.

Zitieren

APA

Vique‐Sánchez, J. L., Lujano, P. G. L., Fonseca, K. A. R., & Benítez‐Cardoza, C. G. (2023). Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity. ChemistrySelect, 8(16). https://doi.org/10.1002/slct.202300196

Vancouver

Vique‐Sánchez JL, Lujano PGL, Fonseca KAR, Benítez‐Cardoza CG. Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity. ChemistrySelect. 2023;8(16). doi:10.1002/slct.202300196

BibTeX
@article{ViqueSnchez2023,
  author = {Vique‐Sánchez, José Luis and Lujano, Paola Guadalupe López and Fonseca, Karla Alejandra Rodríguez and Benítez‐Cardoza, Claudia Guadalupe},
  title = {Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity},
  journal = {ChemistrySelect},
  year = {2023},
  volume = {8},
  number = {16},
  doi = {10.1002/slct.202300196}
}
Kostenlos starten →